Abstract
About 80-90% of post-transfusional hepatitis and 50% of sporadic hepatitis, so called non A non B Hepatitis, are produced by HVC. The prevalence of Anti-HVC is about 0.4-2.2% in blood donors. After an acute HVC infection, 50-60% of patients will progress to a chronic state, and 20% of then will have an hepatic cirrhosis. The objetive of this study was to evaluate the anti HVC prevalence in different high risk groups. Subjects and Methods: 131 patients considered as high risk groups were selected:a)69 with hepatic disease (HD,34 boys, r:1m-18y);b)23 with hemato-oncologic disease (H-O, 13 boys, r:2.5-16y);c) 39 with chronic renal failure (CRF, 19 boys;r:3-19y). Hospital's blood donors (BD) population was used as control group. Anti-HVC was detected by 2nd. generation immunoenzyme assay and confirmed by a 2nd. sample. Results:
Conclusion:1)Patients of the 3 study groups had a higher prevalence than the control group (p 0.05);2)Screening of anti-HVC seems mandatory in services of Hemotherapy;3)Patients with CRF should be screened for anti-HVC, because thier renal transplant may be conditioned by the presence of hepatic involvement.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ramonet, M., Vazquez, L., Gomez, S. et al. PREVALENCE OF HEPATITIS C VIRUS (HVC) ANTIBODIES IN HIGH RISK GROUPS. Pediatr Res 33, 660 (1993). https://doi.org/10.1203/00006450-199306000-00032
Issue Date:
DOI: https://doi.org/10.1203/00006450-199306000-00032